Kartos Therapeutics, Inc. clinical trials
Acquired by Ipsen, Aug 21, 2026 · source ↗
The registry lists 16 studies whose lead sponsor is Kartos Therapeutics, Inc.. 7 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 25, 2025.
Before and after it joined Ipsen
- First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- 16
- First submitted after Kartos Therapeutics, Inc. became part of Ipsen
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Kartos Therapeutics, Inc.16 studies
Something wrong with this grouping? Tell us on the Ipsen page.
Studies
Recruiting first, then most recently updated. Showing 16 of 16. All Ipsen studies →
- Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to RuxolitinibRecruitingNCT06479135Phase 3
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial CancerRecruitingNCT05797831Phase 2/3
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor TreatmentRecruitingNCT03662126Phase 2/3
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell CarcinomaRecruitingNCT03787602Phase 1/2
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MFRecruitingNCT04640532Phase 1/2
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve MyelofibrosisRecruitingNCT04878003Phase 2
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- KRT-232 and TKI Study in Chronic Myeloid LeukemiaRecruitingNCT04835584Phase 1/2
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung CancerWithdrawnNCT05705466Phase 1/2
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)TerminatedNCT04113616Phase 1/2
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung CancerTerminatedNCT05027867Phase 2
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLLStatus unknownNCT04502394Phase 1/2
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to RuxolitinibStatus unknownNCT04485260Phase 1/2
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple MyelomaCompletedNCT01723020Phase 1
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- A Phase 1b/2a Study Evaluating AMG 232 in Metastatic MelanomaCompletedNCT02110355Phase 1
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia VeraStatus unknownNCT03669965Phase 2
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen
- A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid LeukemiaCompletedNCT02016729Phase 1
Sponsor listed in the registry: Kartos Therapeutics, Inc. · First submitted before Kartos Therapeutics, Inc. became part of Ipsen